Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2024年9月10日
	新闻
	AZ's lung cancer drug disappoints - European Biotechnology Magazine European Biotechnology A Phase III trial evaluating AstraZeneca and Daiichi Sankyo's potential "blockbuster" lung cancer drug Dato-DXd showed no significant improvement ... 标记为不相关
	Report: High risk of lung cancer from respirable crystalline silica even below the current ... Medical Xpress Recent epidemiological studies have shown excess lung cancer risk among workers exposed to RCS even in the absence of silicosis although silicosis ... 标记为不相关
	AstraZeneca, Daiichi unpack Dato-DXd's overall survival fail - Fierce Biotech Fierce Biotech lung cancer The FDA accepted a filing of datopotamab deruxtecan for approval in previously treated nonsquamous non-small cell lung cancer in February. 标记为不相关
	Osimertinib Plus Savolitinib Exhibits Clinically Meaningful ORR vs Osimertinib in EGFR+ NSCLC OncLive ... lung cancer (NSCLC), according to data from the phase 2 FLOWERS trial (NCT05163249) presented at the 2024 IASLC World Conference on Lung Cancer. 1. 标记为不相关
	BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer ... Morningstar Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈